Lascufloxacin

Drug Profile

Lascufloxacin

Alternative Names: KRP-AM1977; KRP-AM1977X; KRP-AM1977Y

Latest Information Update: 16 Nov 2016

Price : $50

At a glance

  • Originator Kyorin
  • Class Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Pyrrolidines; Quinolones; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia; Otorhinolaryngological infections; Respiratory tract infections

Most Recent Events

  • 01 Jul 2016 Phase-III clinical trials in Community-acquired pneumonia in Japan (IV) (JapicCTI-163301)
  • 01 Jul 2016 Phase-III clinical trials in Respiratory tract infections in Japan (IV) (JapicCTI163302)
  • 25 Jun 2016 Kyorin Pharmaceutical plans a phase III trial for Community-acquired pneumonia (In adolescents, In adults) in Japan (IV, Infusion) (JapicCTI-163301)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top